Univariate and multivariate COX regression analyzes of overall survival since diagnosis of advanced disease in patients with advanced LCNEC
| Parameters | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| ICI: yes versus no | 0.59 (0.38 to 0.93) | 0.02 | 0.58 (0.34 to 0.98) | 0.04 |
| Chemotherapy: yes versus no | 0.33 (0.20 to 0.52) | <0.001 | 0.41 (0.23 to 0.73) | 0.002 |
| Age | 1.15 (1.02 to 1.29) | 0.02 | 1.00 (0.97 to 1.03) | 0.89 |
| Sex: male versus female | 1.23 (0.81 to 1.88) | 0.34 | ||
| Smoking: yes versus no | 1.00 (0.55 to 1.81) | 1.00 | ||
| Stage at DX:I/II vs III/IV | 1.56 (0.86 to 2.81) | 0.15 | ||
| ECOG PS:2–4 vs 0/1 | 2.66 (1.65 to 4.31) | <0.001 | 2.3 (1.37 to 3.84) | 0.002 |
| Brain metastases: yes versus no | 1.40 (0.89 to 2.20) | 0.15 | ||
| Liver metastases: yes versus no | 1.83 (1.19 to 2.80) | 0.005 | 1.70 (1.06 to 2.74) | 0.03 |
| Molecular subtype: NSCLC-like vs others | 0.56 (0.28 to 1.11) | 0.10 | ||
Statistically significant differences are indicated in bold.
DX, diagnosis; ECOG PS, Eastern Cooperative Oncology Group performance status score; ICI, immune check-point inhibitors; LCNEC, large-cell neuroendocrine tumors of lung; NSCLC, non-small-cell lung cancer.